Aktie A3ESZB REGENERX BIOPHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen RegeneRx Biopharmaceuticals, Inc.

Aktien

A3ESZB

US75886X3061

RGRX

Markt geschlossen - OTC Markets
Andere Börsenplätze
 19:15:27 01.05.2024 		% 5 Tage % 1. Jan.
0,0014 USD 0,00 % Intraday Chart für RegeneRx Biopharmaceuticals, Inc. 0,00 % +16,67 %
2023 RegeneRx Biopharmaceuticals, Inc. meldet Ergebniszahlen für das erste Quartal zum 31. März 2023 CI
2023 RegeneRx Biopharmaceuticals, Inc. meldet Ergebnis für das am 31. Dezember 2022 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
RegeneRx Receives Stockholder Approval for Reverse Stock Split
RegeneRx Biopharmaceuticals : Submission of Matters to a Vote of Security Holders - Form 8-K
RegeneRx To Extend Consent Solicitation Vote
RegeneRx Biopharmaceuticals, Inc. announced that it has received $0.05 million in funding from Essetifin S.p.A.
RegeneRx Biopharmaceuticals, Inc. announced that it expects to receive $0.175 million in funding
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
RegeneRx Biopharmaceuticals, Inc. - First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical trial with RGN-259
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259
RegeneRx Issues Letter To Stockholders
REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operation. (form 10-K)
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
Thymosin Beta 4 Research Leads Toward Potential Future Anti-Aging Therapy
Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy
Regenerx Biopharmaceuticals, Inc. Reports New Scientific Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy
REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3ESZB Aktie
  4. Nachrichten RegeneRx Biopharmaceuticals, Inc.
  5. Andere Sprachen